Journal of Allergy and Clinical Immunology
Asthma outcomes: Healthcare utilization and costs
Section snippets
Definition and methodology for measurement
Collecting and reporting asthma-related events and resource utilization make it possible to compare events and outcomes across studies and to achieve a more complete and standardized accounting of resource use. Healthcare events include:
- •
hospitalizations;
- •
ED visits;
- •
unscheduled outpatient visits;
- •
scheduled (preventive) outpatient visits;
- •
subspecialist care; and
- •
remote care.
For the purposes of measuring healthcare utilization and cost, each healthcare event and occurrence of resource use (eg, short
Cost and cost-effectiveness analysis
The section below provides an overview of methods for assigning value to measured units of healthcare utilization, other intervention-related resources, and other outcomes that contribute to the direct and indirect costs of asthma interventions and morbidity. An important consideration across all types of resources when valuing an intervention is distinguishing between those activities that relate to research and those that are part of the intervention. Under most circumstances, the research
Future directions
The subcommittee identified 4 priority topics for additional research:
- 1.
Development of survey instruments. Analysts sometimes rely on poorly validated convention and historical documents from national surveys to elicit measures of healthcare utilization from patients and providers. Development of standardized and validated survey instruments for prospective and retrospective data collection for asthma healthcare and other asthma-related events for both provider-reported and participant-reported
References (66)
- et al.
Measuring costs and consequences in economic evaluation in asthma
Respir Med
(2003) - et al.
Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season
Am J Obstet Gynecol
(2003) - et al.
Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department
Ann Emerg Med
(2004) - et al.
Implementing a disease management intervention for depression in primary care: a random work sampling study
Gen Hosp Psychiatry
(2003) - et al.
Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma
Value Health
(2008) - et al.
Relations of change in condition severity and school self-concept to change in achievement-related behavior in children with asthma or epilepsy
J School Psychol
(2000) - et al.
School readiness among urban children with asthma
Ambul Pediatr
(2001) - et al.
The cost-effectiveness of an inner-city asthma intervention for children
J Allergy Clin Immunol
(2002) - et al.
Cost-effectiveness of a home-based environmental intervention for inner-city children with asthma
J Allergy Clin Immunol
(2005) The ISPOR Good Practice Modeling Principles–a sensible approach: be transparent, be reasonable
Value Health
(2003)
Quality of care for childhood asthma: estimating impact and implications
Pediatrics
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice
Am J Respir Crit Care Med
A summary of studies of interviewing methodology
Vital Health Stat 2
Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma
Allergy
2008 National Health Interview Questionnaire–Sample Adult
SLAITS National Asthma Survey National Sample–2003 CATI specifications
2009 Behavioral Risk Factor Surveillance System Questionnaire
Alleviate Asthma Tool Kit: Section VIII: sample documents and materials
Transformations, means, and confidence intervals
BMJ
The importance of the normality assumption in large public health data sets
Annu Rev Public Health
Quartiles, quintiles, centiles, and other quantiles
BMJ
Status of childhood asthma in the United States, 1980-2007
Pediatrics
Impact of asthma intervention in two elementary school-based health centers in the Bronx, New York City
Pediatr Pulmonol
A randomized clinical trial of clinician feedback to improve quality of care for inner-city children with asthma
Pediatrics
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma, Full Report 2007
Preventable hospitalizations and access to health care
JAMA
A systematic review of risk factors associated with near-fatal and fatal asthma
Can Respir J
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
BMC Health Serv Res
Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study
Hemodial Int
Assessing the total costs of blood delivery to hospital oncology and haematology patients
Curr Med Res Opin
Documentation of chemotherapy infusion preparation costs in academic- and community-based oncology practices
J Natl Compr Canc Netw
Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study
Am J Health Syst Pharm
Estimating paid and unpaid hours of personal assistance services in activities of daily living provided to adults living at home
Health Serv Res
Cited by (0)
The Asthma Outcomes workshop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; and the US Environmental Protection Agency funded the publication of this article and all other articles in this supplement.
Disclosure of potential conflict of interest: S. D. Sullivan has received research support from Merck. J. D. Campbell is a consultant for VeriTech Corp and has received research support from the Agency for Healthcare Research and Quality. R. W. Grundmeier has received research support from AHRQ, the NIH, and MCHB. T. V. Hartert has received research support from the NIH and AHRQ; is an Associate Editor for the ATS; and is a consultant for Merck. The rest of the authors declare that they have no relevant conflicts of interest.